Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Industrial Data Services for Quality Control in Smart Manufacturing (i4Q)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Technologies for Factories of the Future
Action type: Innovation actions
Countries involved: Germany,Spain,Austria,Italy,Italy,Italy,Israel,Germany,Spain,Italy,Türkiye,Belgium,Poland,Bulgaria,Greece,Portugal,Portugal
Call: Quality control in smart manufacturing (IA) (H2020-NMBP-TR-IND-2020-singlestage, 2020)
Start date: 2021-01-01
End date: 2024-05-31
Duration (months): 41.0
Total project cost (EUR): 11442342.51
EU funding (EUR): 9997485.87
Participants: 26
Project status: SIGNED

i4Q Project aims to provide an IoT-based Reliable Industrial Data Services (RIDS), a complete suite consisting of 22 i4Q Solutions, able to manage the huge amount of industrial data coming from cheap cost-effective, smart, and small size interconnected factory devices for supporting manufacturing online monitoring and control. The i4Q Framework will guarantee data reliability with functions grouped into five basic capabilities around the data cycle: sensing, communication, computing infrastructure, storage, and analysis and optimization. i4Q RIDS will include simulation and optimization tools for manufacturing line continuous process qualification, quality diagnosis, reconfiguration and certification for ensuring high manufacturing efficiency, leading to an integrated approach to zero-defect manufacturing. The i4Q RIDS will be demonstrated in 6 Uses Cases from relevant industrial sectors and representing two different levels of the manufacturing process: machine tool providers and production companies. i4Q pan-European consortium entails Industrial partners: WHIRLPOOL (White goods manufacturer), BIESSE (Wood industrial equipment), FACTOR (Metal machining), RIASTONE (Ceramic pressing), FARPLAS (Plastic injection) and FIDIA (Metal industrial equipment); Implementers: TIAG (Industrial Communication Protocols and Standards), CESI (Machine tools, Advanced Materials, Micro-technology) and AIMPLAS (Thermoplastic and thermosetting plastic materials); Technology Providers: IBM (Information Technologies Company), ENGINEERING (Software and Services Company), ITI (Information Technologies Institute), KNOWLEDGEBIZ (Information Systems Company), EXOS (Operations Consulting Company); R&D partners: CERTH (Research Institute), IKERLAN (Technological Centre), BIBA (Research Institute), UPV (University), TUBERLIN (University), UNINOVA (Research Institute); Specialist partners: FUNDINGBOX (Exploitation), INTEROP-VLAB (Dissemination), DIN (Standardisation), LIF (Legal).

Keywords: product quality,process quality,data quality,data reliability,blockchain,virtual sensors,digital twins,process simulation,process optimization,zero defect manufacturing
Advanced Pain Control – An innovation in pain control for those suffering from secondary bone cancer (APAC)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Sweden
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-07-01
End date: 2019-12-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

This Phase 1 project will enable Scandinavian ChemoTech AB (ChemoTech) to develop a business plan for Dynamic-ElectroEnhanced Pain Control (D-EEPC). This will include clinical and market feasibility, with a strong business development and commercialisation strategy. Approximately 25% of all cancer patients are affected by secondary bone cancer; which is difficult to find and treat. 20-30% of these patients do not respond to current systemic therapies and pain control with narcotic analgesics, radiation therapy and surgery. This patient population continues to experience potentially debilitating back pain. To address this, ChemoTech has developed D-EEPC - a game-changing pain reduction treatment for secondary bone cancer. It operates by sending short, high voltage electric pulses in combination with a low concentration of a cytostatic drug to reduce tumour size in the spine or bones. This reduces pain caused by pressure on nerves. The different voltage settings and use of an applicator with different sizes allows treatment of hard-to-treat cancers and distinguishes D-EEPC from its competitors. Development of D-EEPC and research supporting its efficacy and safety to date is extremely promising but requires full clinical validation and an optimal business strategy. The proposed Phase 1 project will enable the company to define the pathway to implement for successful commercialisation.

Keywords: electrochemotherapy,bone metastasis,pain management,secondary bone cancer
ENABLING THE BIG DATA PIPELINE LIFECYCLE ON THE COMPUTING CONTINUUM (DataCloud)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: Research and Innovation actions
Countries involved: Austria,Italy,Germany,Spain,Italy,Sweden,Norway,Greece,Norway,France,Portugal
Call: Cloud Computing: towards a smart cloud computing continuum (H2020-ICT-2020-2, 2020)
Start date: 2021-01-01
End date: 2023-12-31
Duration (months): 36.0
Total project cost (EUR): 4999996.25
EU funding (EUR): 4999996.25
Participants: 11
Project status: SIGNED

DataCloud provides a novel paradigm covering the complete lifecycle of managing Big Data pipelines through discovery, design, simulation, provisioning, deployment, and adaptation across the Computing Continuum. Big Data pipelines in DataCloud interconnect the end-to-end industrial operations of collecting pre-processing and filtering data, transforming and delivering insights, training simulation models, and applying them in the cloud to achieve a business goal. DataCloud delivers a toolbox of new languages, methods, infrastructures, and prototypes for discovering, simulating, deploying, and adapting Big Data pipelines on heterogeneous and untrusted resources. DataCloud separates the design from the run-time aspects of Big Data pipeline deployment, empowering domain experts to take an active part in their definitions. The main exploitation targets the operation and monetization of the toolbox in European markets, and in the Spanish-speaking countries of Latin America. Its aim is to lower the technological entry barriers for the incorporation of Big Data pipelines in organizations’ business processes and make them accessible to a wider set of stakeholders regardless of the hardware infrastructure. DataCloud validates its plan through a strong selection of complementary business cases offered by SMEs and a large company targeting higher mobile business revenues in smart marketing campaigns, reduced production costs of sport events, trustworthy eHealth patient data management, and reduced time to production and better analytics in Industry 4.0 manufacturing. The balanced consortium consists of 11 partners from eight countries. It has three strong university partners specialised in Big Data, distributed computing, and high-productivity languages, led by a research institute. DataCloud gathers six SMEs and one large company (as technology providers and stakeholders/users/early adopters) that prioritise the business focus of the project in achieving high business impacts.

Keywords: big data,data pipelines,data workflows,toolbox,blockchain,process mining,computing continuum,edge computing
Personalised Quantitative Upper Extremity Assessment for Stroke Rehabilitation (Rehab-Assessment)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: United Kingdom
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2022-01-01
End date: 2024-02-27
Duration (months): 24.0
Total project cost (EUR): 212933.76
EU funding (EUR): 212933.76
Participants: 1
Project status: SIGNED

Globally, 15 million people suffer a stroke every year, causing 6 million deaths and leaving another 5 million permanently disabled, which makes stroke the second leading cause of disability. In the Europe, it is the most common cause of morbidity and long-term disability, and has significant socioeconomic consequences for patients, their partners and society. Thus far, upper limb weakness remains the biggest and most challenging disability, due to the complexity of movement required in daily living and its generally slower and less complete recovery. More than 50% of stroke survivors still have upper extremity hemiparesis one year after stroke. Neuro rehabilitation is the main approach to improve upper extremity motor outcome, and previous studies have demonstrated that patients can regain considerable motor functions after intensive training. With the number of people surviving a stroke soaring, more and more rehabilitation programs are delivered with minimal involvement of a physiotherapist due to limited resource available, and the success of this approach depends on the accurate assessment of stroke patients’ movement impairment. In collaboration with with the National Demonstration Centre in Rehabilitation Medicine, Leeds Teaching Hospitals NHS Trust, my vision is therefore to establish a comprehensive, quantitative, objective and personalised Motor Impairment Index (MII), via benchmarking the impaired arm movement to healthy arm mirrored exercise to quantify the motor impairment. This approach will increase the likelihood of successful rehabilitation leading to improved quality of life for millions of people affected by stroke. This application focuses on developing innovative healthcare technologies for stroke patients; but it could also potentially benefit millions of people with conditions such as multiple sclerosis, brain tumours and spinal cord injury, as well as people with musculoskeletal conditions or trauma.

Keywords: wearable sensing,rehabilitation,machine learning
Converged wireless access for reliable 5G MTC for factories of the future (Clear5G)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: Research and Innovation actions
Partnership: 5G PPP (cPPP)
Countries involved: Taiwan, Province of China,Türkiye,Türkiye,Greece,France,Netherlands,United Kingdom,United Kingdom
Call: 5G PPP Convergent Technologies (H2020-ICT-2016-2, 2016)
Start date: 2017-09-01
End date: 2020-05-31
Duration (months): 33.0
Total project cost (EUR): 3319116.25
EU funding (EUR): 2498616.25
Participants: 12
Project status: CLOSED

Clear5G’s objective is to design, develop, validate, and demonstrate an integrated convergent wireless network for Machine Type and Mission Critical Communication (MTC/MCC) services for Factories of the Future (FoF). Clear5G will deliver technical solutions addressing the challenges of massive deployment of connected devices, security, ultra-low latency and ultra-high reliability in FoF applications, like remote maintenance and closed loop control systems. The requirements of these complex scenarios will be met through the convergence of different wireless technologies, enabled by protocol and architecture enhancements proposed by Clear5G. Clear5G will focus on providing PHY, MAC, and architectural enhancements to meet the strict requirements of FoF applications in terms of KPIs: latency, reliability, connection density, spectrum, and energy efficiency, thus contributing to the ITU-R objectives (e.g. 1000 fold connection density) for the next generation mobile network. The Clear5G team comprises a combination of European and Taiwanese successful, innovative, and well known major corporations, SMEs, as well as research and academic institutions. The partners have proven know-how in architecture, resource management, protocol enhancements, standardization, prototyping, and demonstration. Proof of concepts will be tested on the 5GIC testbed in Europe, while the final system demonstration, showing the tight integration and cooperation of manufacturing and the Clear5G enhanced network, will be implemented on the III testbed in Taiwan. Clear5G brings together a strong and diverse set of European and Taiwanese partners, including partners from the FoF sector; the complementarity of team, skills and expertise will bring added value to 5G research on both sides and will deepen international cooperation, serving as a showcase of 5G empowering vertical industries. The partners will contribute to relevant standardisation in both the communication and the manufacturing domains.

Keywords: converged access,machine type traffic,factories of the future,5g network
EUropean QUalification Approach for Low EnrIched Fuel sYstems for secure production supply of medical isotopes (EU-QUALIFY)

Framework: Horizon 2020 — Euratom
Programme: Nuclear fission and radiation protection
Theme: Research infrastructure
Action type: Research and Innovation actions
Countries involved: Germany,Belgium,France,France,France
Call: Optimised fuels for production of medical radioisotopes (NFRP-2019-2020, 2019)
Start date: 2020-10-01
End date: 2024-09-30
Duration (months): 48.0
Total project cost (EUR): 9044296.25
EU funding (EUR): 7798926.0
Participants: 6
Project status: SIGNED

One of the biggest challenges for European research reactors is securing their nuclear fuel supply to ensure a sustainment of medical isotopes for Europe and the world. This is particularly true for the few operating High Performance Research Reactors (HPRRs) in Europe, which produce the vast majority of medical isotopes. The obligation to convert them from high to low enriched uranium (LEU) nuclear fuels while keeping similar radioisotopes production ratios makes it necessary to develop higher uranium density fuels. The R&D related to that topic was started in previous EURATOM projects (HERACLES-CP and LEU-FOREvER). The main goal of the EU-QUALIFY project is to qualify such fuels and qualify the capability to fabricate such fuels. This will be done by a multi-disciplinary consortium composed of fuel designers/manufactures, reactor operators, research organizations and a university, namely: SCK CEN, CEA, CERCA, ILL, TUM, and G-INP. The EU-QUALIFY project will build on previous LEU fuel development work with specific focus on the qualification of three particular types of fuels: the dispersed U-Mo, the monolithic U-Mo and the high-loaded dispersed U3Si2 fuels. This qualification will be accomplished through fabrication and concurrent qualification of pilot manufacturing equipment and processes, irradiation under representative irradiation conditions, post-irradiation examinations, as well as modelling of the in-pile behavior to support LEU conversion safety analyses. This project will contribute to ensuring the availability of HPPR’s, and thus enhance the security of the EU’s capacity in the production of medical radioisotopes. It will thus contribute to health care through provision of innovative medical radioisotopes necessary for diagnostic and therapy and will support European industry by maintaining access to research reactor irradiation capabilities.

Keywords: nuclear fuel qulaification material test and research reactors
X-ray-waveforms at the Space-Time Resolution Extreme for Atomic-scale Movies (XSTREAM)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Fundamental constituents of matter
Panel description: Particle, nuclear, plasma, atomic, molecular, gas, and optical physics
Countries involved: Austria
Call: ERC Starting Grant (ERC-2016-STG, 2016)
Start date: 2017-08-01
End date: 2023-07-31
Duration (months): 72.0
Total project cost (EUR): 1513335.34
EU funding (EUR): 1513335.34
Participants: 1
Project status: SIGNED

Nonlinear optics revolutionized the ability to create directed, coherent beams particularly in spectral regions where lasers based on conventional population inversion are not practical. New breakthroughs in extreme nonlinear optics promise a similar revolution in the X-ray regime. In a dramatic and unanticipated breakthrough, an international team lead by the PI demonstrated that the high harmonic generation process (HHG) driven by mid-IR lasers can be used to generate keV photons, implementing a >5000 order nonlinear process, while still maintaining the full phase matching that is necessary for good conversion efficiency. This work represents the most extreme, fully coherent upconversion for electromagnetic waves in the 50 year history of nonlinear optics. Moreover, the limits of HHG are still not understood, either theoretically or experimentally. It may be possible to generate coherent hard X-rays using a tabletop-scale apparatus. In another surprising breakthrough, the PI showed that UV-driven HHG in multiply ionized plasma can be also highly efficient, representing a 2nd route towards the X-ray region. Remarkably, this regime provides X-rays with contrasting spectral and temporal properties. Furthermore, by shaping the polarization of a bi-color mid-IR driving laser the PI, the JILA team in collaboration with Technion, demonstrated robust phase matching of circularly polarized soft X-rays. In the proposed work, the fundamental atomic, phase matching plus group velocity matching limits of HHG in the multi-keV X-ray regime will be explored using the 3 most promising, complimentary approaches: 1) mid-IR driven HHG, 2) UV driven HHG, and 3) all-optical quasi phase matching. The knowledge gained as a result of this effort will identify the best path forward for generating bright coherent X-ray beams on a tabletop, at photon energies of 1-10 keV and greater with unprecedented attosecond-to-zeptosecond pulse durations, and arbitrary polarization state.

Keywords: coherent soft and hard x rays,high order harmonic generation,extreme nonlinear optics,attosecond x ray pulses,zeptosecond x ray pulses,phase matching,group velocity matchng
Towards Uncovering the Splicing Code of the Gigantic Gene Titin in Familial Dilated Cardiomyopathy (TITINmap)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Global Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany,United States
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2022-01-01
End date: 2023-12-31
Duration (months): 24.0
Total project cost (EUR): 176036.16
EU funding (EUR): 176036.16
Participants: 2
Project status: CLOSED

The sarcomeric protein titin (TTN) is mutated in 30% of patients with familial dilated cardiomyopathy (DCM), a common heart disease that is a global threat to the aging society. Aberrant alternative splicing of TTN is causally linked to DCM, therefore, to understand mechanisms of TTN splicing is crucial for developing therapeutic options, which so far do not exist for DCM. RBM20, a protein that regulates alternative splicing of TTN, is also mutated in many patients with an aggressive form of DCM. How RBM20 mediates alternative splicing of TTN is largely unknown. Due to its gigantic size, TTN mRNA is often precluded from transcriptome-wide single-cell analysis. Here, I aim to understand alternative splicing of TTN mediated by RBM20 on a single-cell level. To this end, I propose to develop a method for the detection of all transcript isoforms that can be produced by the 364 exons of TTN. Using this tool, termed TITIN-seq, together with complementary stem cell-based assays, I seek to analyze changes in the repertoire of TTN isoforms upon disease-relevant mutations in the RBM20 gene. Moreover, TITIN-seq is used to identify novel splice regulators of TTN, which, together with RBM20, could complete the picture of alternative splicing of TTN. The overarching goal is to construct a comprehensive map of TTN splicing by integrating data of all its isoforms in single cells and its regulatory proteins. I envision that knowledge of such a splice map can be exploited for developing therapeutic strategies to revert aberrant splicing of TTN in patients with DCM.

Keywords: dilated cardiomyopathy,titin,long read sequencing,alternative splicing,single cell transcriptomics,ipscs
AGeing effects on human aORta: from shApe to flowS (AGORAs)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Global Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Italy,Canada
Call: Marie Skłodowska-Curie Individual Fellowships (IF-GF) (H2020-MSCA-IF-2014, 2014)
Start date: 2016-05-16
End date: 2019-05-15
Duration (months): 36.0
Total project cost (EUR): 229761.0
EU funding (EUR): 229761.0
Participants: 2
Project status: TERMINATED

Age-related remodeling of the aorta is associated with alterations in morphology and hemodynamics . These alterations are involved and accelerated in the presence of cardiovascular diseases (CVDs), suggesting that they are the likely culprits that underlie the increased cardiovascular risk associated with ageing . However, an advanced characterization of the age-related morphological/hemodynamic alterations and on their synergistic interplay is missing, mainly because encumbered by time-consuming operator-dependent tasks. In this 36 months global fellowship (University of Toronto, Canada and Politecnico di Torino, Italy), the potential clinical utility of such a characterization will be addressed, developing tools for the quantitative assessment of the age-associated alterations in a large-scale cross-sectional dataset of aortas from subjects with successful ageing. After training on phase-contrast magnetic resonance imaging (PCMRI) technique, for each subject the 4D velocity field will be acquired. Quantitative morphometric parameters will be defined and evaluated in vivo. To investigate aortic hemodynamics, PCMRI will be complemented by computational fluid dynamics (CFD) to overcome PCMRI limitations on temporal/spatial resolution and wall shear stress quantification . The impact of CFD assumptions will be assessed by validating CFD results with PCMRI measurements. To improve CFD results accuracy, in the return phase PCMRI data will be incorporated into the numeric simulations, through the assimilation of the acquired flow fields into the CFD solver. Descriptors quantifiable in vivo and able to simplify the understanding of the complex 4D hemodynamic and of age-associated remodeling will be defined. The new tools for diagnostic/prognostic purposes will be integrated within the open-source Vascular Modelling ToolKit, to facilitate and streamline the diagnosis and monitoring of a wider range of CVDs when applied to other vascular districts (e.g. carotid, aneurysm).

Keywords: phase contrast mri,morphometry,biofluid dynamics,hemodynamics,computational fluid dynamics,data assimilation